MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer

Zhou, Yifei; Wu, Donghai; Tao, Jun; Qü, Ping; Zhou, Zhengdong; Hou, Jianquan

doi:10.3109/00365599.2012.748821

Cited by 66 publications

(50 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Originally, a number of studies determined that miR-133 is critical in regulating heart and skeletal muscle development (18,19). However, a more recent study demonstrated that miR-133 is aberrantly expressed in tumors, and that miR-133a/b can inhibit the proliferation, and metastasis of bladder and prostate cancer by regulating the expression of the epidermal growth factor receptor (20,21). In addition, previous studies have observed a significant downregulation of miR-133a/b in head and neck neoplasms, lung cancer, esophageal cancer, colon cancer, renal carcinoma, prostate cancer, and other malignancies (22)(23)(24)(25).…”

Section: Discussionmentioning

confidence: 99%

Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer

Chen

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to screen for and identify microRNAs (miRNAs/miRs) that are associated with gastric cancer and to clarify the role of these miRNAs in gastric cancer. Thus, the differential expression of a panel of miRNAs in two pairs of gastric cancer tissues and their matched adjacent healthy tissues was investigated by performing a microarray analysis. To verify the results of this screen, 56 gastric cancer tissues were analyzed for the selected miRNAs using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The association between the expression of a specific miRNA and the clinical data relating to the tissue samples [including age, gender, tumor size, tumor node metastasis (TNM) stage and lymph-node metastasis] were subsequently examined. A total of 31 differentially expressed miRNAs were identified in the miRNA array. Using RT-qPCR to verify these results, it was determined that 10 miRNAs exhibited high mRNA expression levels and 13 miRNAs exhibited a low expression in the gastric cancer tissue samples, while 8 miRNAs did not demonstrate an association with gastric cancer. Thus, the microarray and RT-qPCR results demonstrated 74.2% (23/31 miRNAs) agreement. The association between the 23 miRNAs and the clinicopathological characteristics of the gastric cancer samples was investigated. It was identified that the expression levels of miR-551b-3p, miR-133b, miR-100-5p and miR-363-3p were significantly downregulated in the gastric cancer tissues, and this downregulation was closely correlated with the degree of differentiation (i.e., tumor grade), TNM stage and lymph-node metastasis (P<0.05). By contrast, the expression of miR-215 was significantly upregulated in the gastric cancer tissues, and its expression level was correlated with tumor differentiation, TNM stage and lymph-node metastasis (P<0.05). Furthermore, miR-200a-3p was upregulated in the gastric cancer tissues and its expression was significantly more prevalent in male patients compared with female patients (P<0.05). miR-429 was upregulated in the gastric cancer tissues and its expression was significantly higher in patients who were >50 years of age (P<0.05). These data indicate that a number of these miRNAs may be important in the development of gastric cancer. In particular, miR-551b-3p, miR-133b, miR-100-5p and miR-363-3p may act as tumor suppressors in the development of gastric cancer. By contrast, miR-215 appears to exhibit oncogenic properties and promote the development of gastric cancer. In addition, the abnormal expression of miR-200a-3p may be associated with gender, while the abnormal expression of miR-429 may be associated with age in patients with gastric cancer. However, additional studies are required to delineate the underlying mechanisms of the association, and to explore their potential as valid biomarkers in the diagnosis, classification and prognosis of gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer

Chen

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…MiR-133b is located on chromosome 18 in the same bicistronic unit with miR-133a (Zhou et al, 2013). It has long been recognized as a muscle specific miRNA that may regulate myoblast differentiation and participate in many myogenic diseases (Koutsoulidou et al, 2011;Panguluri et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

MiR-133b Acts as a Tumor Suppressor and Negatively Regulates TBPL1 in Colorectal Cancer Cells

Xiang

Li²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…In addition, it has been suggested that miRNAs may be potential target for the treatment of cancer (24). It has been reported that miRNA (miR)-133a is among the most frequently downregulated miRNAs in various types of human malignancy, including HCC (25), renal cell carcinoma (26), esophageal squamous cell carcinoma (27), bladder cancer (28), ileal carcinoid (29) and rhabdomyosarcoma (30). The aim of the present study was to determine the effects of miR-133a on cell proliferation, colony formation, migration and invasion in HCC HepG2 and SMMC-7721 cell lines, as well as to investigate whether matrix metallopeptidase 9 (MMP-9) may be a target of miR-133a.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-133a inhibits cell proliferation, colony formation ability, migration and invasion by targeting matrix metallopeptidase 9 in hepatocellular carcinoma

Chen

Zhao

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. is downregulated in various types of human malignancy, including hepatocellular carcinoma (HCC), renal cell carcinoma, esophageal squamous cell carcinoma, bladder cancer, ileal carcinoid and rhabdomyosarcoma. The aim of the present study was to examine the effects of miR-133a on HCC cell proliferation, colony formation, migration and invasion. miR-133a was transfected into the HCC HepG2 and SMMC-7721 cell lines and the expression levels of miR-133a were determined; in addition, cell viability assays, colony formation assays, cell migration assays, cell invasion assays, western blot analyses and luciferase assays were performed in the HCC cell lines. The results demonstrated that miR-133a significantly inhibited cell proliferation, colony formation, migration and invasion in HepG2 and SMMC-7721 cells. To the best of our knowledge, the present study also provided the first evidence that miR-133a directly downregulated the expression of matrix metallopeptidase 9 (MMP-9) in the HCC cells. In conclusion, the results of the present study indicated that miR-133a may have suppressed cell proliferation, colony formation, migration and invasion via the downregulation of MMP-9 in HCC cell lines. Therefore, MMP-9 may be used for the development of novel molecular markers and therapeutic approaches to inhibit hepatocellular carcinoma metastasis.

show abstract

MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer

Abstract: This study provided the first glimpse of the functional role of miR-133 in bladder cancer T24 and EJ cells. The results may increase our knowledge on the molecular basis of progression and provide potential therapy for bladder cancer.

Cited by 66 publications

References 33 publications

Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer

Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer

MiR-133b Acts as a Tumor Suppressor and Negatively Regulates TBPL1 in Colorectal Cancer Cells

MicroRNA-133a inhibits cell proliferation, colony formation ability, migration and invasion by targeting matrix metallopeptidase 9 in hepatocellular carcinoma

Contact Info

Product

Resources

About